Imperative Care has raised $260m in a Series D funding round led by D1 Capital Partners to develop technologies that can improve stroke care.

New investors HealthCor Investments and Innovatus Capital Partners participated in the funding round along with current investors, including Ally Bridge Group, Bain Capital Life Sciences and Ascension Ventures.

The funds will be used to advance the current marketing and development of various Imperative Care technologies in the extensive stroke care continuum.

In addition, the company will use the proceeds to form a strategic network of wholly-owned development subsidiaries in various collaboration areas.

As part of the funding, James Rogers from D1 Capital Partners will also be appointed to Imperative Care’s board of directors.

Imperative Care has acquired a peripheral thrombectomy firm, Truvic Medical, in a stock-for-stock deal in relation to the funding.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

As per the transaction, Truvic will work as a wholly-owned unit of Imperative Care while maintaining its founding leadership team and brand identity.

Furthermore, the Series D funding proceeds will be used to develop and market Truvic’s technologies for peripheral vascular disease treatment.

Imperative Care chairman and CEO Fred Khosravi said: “In addition to our initial focus in the field of stroke, we see natural areas of synergy across unmet patient needs, and we are committed to accelerating those paths to commercialisation.

“To achieve that objective, and beginning with Truvic, we are creating a network of wholly-owned subsidiaries that will leverage synergies where appropriate while at the same time giving the development programmes the independence, specialisation and focus they need to bring important vascular intervention products to the market to meet patient needs as rapidly as possible.”

Two of Imperative Care’s product platforms have received 510(k) clearance from the US Food and Drug Administration.

These platforms are a family of access catheters known as Large Distal Platform, which aids in smooth navigation into the brain’s blood vessels, and the Zoom Aspiration System, which enables clot removal during ischemic stroke.